改良FOLFIRINOX对比吉西他滨联合白蛋白结合型紫杉醇治疗局部晚期胰腺癌的随机II期研究(JCOG1407)
本研究为随机II期研究,比较mFOLFIRINOX与GnP方案治疗局部晚期胰腺癌的疗效。主要终点为1年总生存率,mFOLFIRINOX组为77.4%,GnP组为82.5%。作者认为GnP因缓解率更高、CA19-9反应更好且胃肠道毒性较轻,可作为后续III期试验的候选方案。
要点
- GnP组1年OS为82.5%,mFOLFIRINOX组为77.4%。
- GnP组缓解率42.1%、CA19-9反应率85.0%,优于mFOLFIRINOX组的30.9%和57.1%。
- mFOLFIRINOX组以3-4级腹泻和厌食为主。
核心结论
- 作者认为GnP因缓解率、CA19-9反应更优且胃肠道毒性较轻,可作为后续III期试验的候选方案。
- 两种方案1年生存率均高于吉西他滨单药治疗的历史数据。
研究设计与样本
- 随机II期研究,纳入未经治疗的局部晚期胰腺癌患者,按1:1随机分配至mFOLFIRINOX组或GnP组。
- 样本量设定为124例,旨在以最小概率0.85选择更有效的方案,并检验1年OS<53%的无效假设。
- 共从29家机构入组126例患者,其中125例符合条件。
主要发现
- mFOLFIRINOX组1年OS为77.4%(95% CI 64.9-86.0),GnP组为82.5%(95% CI 70.7-89.9)。
- mFOLFIRINOX组中位PFS为11.2个月(95% CI 9.9-15.9),GnP组为9.4个月(95% CI 7.4-12.8)。
- mFOLFIRINOX组缓解率为30.9%(95% CI 19.1-44.8),GnP组为42.1%(95% CI 29.1-55.9)。
- mFOLFIRINOX组CA19-9反应率为57.1%(95% CI 41.0-72.3),GnP组为85.0%(95% CI 70.2-94.3)。
- mFOLFIRINOX组以3-4级腹泻和厌食为主。
临床怎么用
- 作者认为GnP可作为后续III期试验的候选方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC). METHODS: Patients with untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was the primary endpoint. The major secondary end-points included progression-free survival (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, and adverse events. The sample size was 124 patients to select a more effective regimen with a minimum probability of 0.85 and to examine the null hypothesis of the 1-year OS <53%. RESULTS: Of the 126 patients enrolled from 29 institutions, 125 were deemed eligible. The 1-year OS was 77.4% (95% CI, 64.9-86.0) and 82.5% (95% CI, 70.7-89.9) in the mFOLFIRINOX and GnP arms, respectively. The median PFS was 11.2 (95% CI, 9.9-15.9) and 9.4 months (95% CI, 7.4-12.8) in the mFOLFIRINOX and GnP arms, respectively. The RR and CA19-9 response rate were 30.9% (95% CI, 19.1-44.8) and 57.1% (95% CI, 41.0-72.3) and 42.1% (95% CI 29.1-55.9) and 85.0% (95% CI, 70.2-94.3) in the mFOLFIRINOX and GnP arms, respectively. Grade 3-4 diarrhoea and anorexia were predominant in the mFOLFIRINOX arm. CONCLUSION: GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy.
引用
- Ozaka M, Nakachi K, Kobayashi S, et al. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Eur J Cancer. 2022. PMID: 36652891. doi:10.1016/j.ejca.2022.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。